Home › Research › Topics › aducanumab
aducanumab
332 studies tagged aducanumab, dated 2000 to 2026-09-09. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
332 studies carry this tag.
Date range
2000 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 26
- Journal of Alzheimer's disease : JAD 21
- The journal of prevention of Alzheimer's disease 20
- Alzheimer's research & therapy 18
- Alzheimer's & dementia (New York, N. Y.) 14
148 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
In this FTIH study the Fc-inactivated anti-Aβ mAb GSK933776 engaged its target in plasma and CSF without causing brain ARIA-E/H in patients with mild AD or MCI.
-
ARIA-H represents a spectrum of MRI findings due to haemosiderin deposition that appears to be related to impaired vascular integrity.
-
Active or passive immunotherapy is expected to slow or stop the pathological process of Alzheimer's disease (AD).
-
Cerebral amyloid angiopathy-related inflammation (CAA-ri), a rare form of vasculitis associated with amyloid-β (Aβ) deposition in vessel walls, has been proposed as a spontaneous human model of the amyloid-related imaging abnormalities (ARIA) occurring after anti-Aβ immunotherapy for the treatment of Alzheimer's disease (AD).
-
Amyloid-related imaging abnormalities (ARIA), thought to reflect immune responses to vascular amyloid, have been detected in several amyloid-modifying therapy trials for Alzheimer's disease (AD).
-
Initial studies suggested that IVIg contained antibodies against monomeric forms of Aβ 5.
-
Among active and passive anti-β-amyloid (Aβ) immunotherapies for Alzheimer's disease (AD), bapineuzumab and solanezumab, two humanized monoclonal antibodies, failed to show significant clinical benefits in mild-to-moderate AD patients in large Phase III clinical trials.
-
The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem.
-
Crenezumab is a humanized anti-abeta monoclonal antibody in development for the treatment of Alzheimer disease (AD).
-
The symptomatic drugs currently on the market for Alzheimer's disease (AD) have no effect on disease progression, and this creates a large unmet medical need.
-
40/100
The memory-enhancing effect of IVIg reported here suggests that Aβ oligomers, effector T cells and the fractalkine pathway are potential pharmacological targets of IVIg in AD.
-
Current treatment options for Alzheimer's disease (AD) are limited to medications that reduce dementia symptoms.
-
Perhaps more definitively than any other class of novel Alzheimer's disease (AD) therapy, pre-clinical studies in mouse models of amyloid β (Aβ) deposition have established the disease-modifying potential of anti-Aβ immunotherapy.
-
Alzheimer's disease, which is characterized by gradual cognitive decline associated with deterioration of daily living activities and behavioral disturbances throughout the course of the disease, is estimated to affect 27 million people around the world.
-
38/100
The DIAN study compared the pathophysiological markers between carriers and non-carriers of mutation for autosomal dominant Alzheimer's disease (AD).
-
An international task force of investigators from academia, industry, nonprofit foundations, and regulatory agencies met in Monte Carlo, Monaco, on October 31, 2012, to review lessons learned from the recent bapineuzumab and solanezumab trials, and to incorporate insights gained from these trials into future clinical studies.
-
SAR228810 is a humanized monoclonal antibody (mAb) binding specifically to soluble protofibrillar and fibrillar forms of Aβ peptide.
-
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) tested bexarotene as a potential β-amyloid-lowering drug for Alzheimer's disease (AD).
-
Our data support the hypothesis that the pathogenesis of CAA-ri may be mediated by a selective autoimmune reaction against cerebrovascular Aβ, directly related to autoantibody concentration and soluble Aβ.
-
Expert opinion Phase III trials showed that bapineuzumab failed to improve cognitive and functional performances in AD patients, and was associated with a high incidence of amyloid-related imaging abnormalities (ARIA).
-
The proposed rating scale provides a reliable and easily implemented instrument to grade ARIA-E imaging findings.
-
Two new combination pediatric vaccines advancing to use in infants Oncolytic viruses successfully delivered intravenously Cuba eliminates hepatitis B among minors under 15 Alzheimer's vaccine trial a success Study: Shingles vaccine safe for patients on immune-suppressing drugs Therapeutic cancer vaccine against metastatic renal cell carcinoma enters Phase 3 Pfizer’s Men B vaccine shows promise in Phase 2 Biovest initiates formal regulatory approval process for BiovaxID in Europe
-
Antibody administration was well tolerated with doses up to 400 mg weekly.
-
Alzheimer's disease (AD) is a debilitating neurodegenerative illness affecting over 35 million people worldwide.
-
38/100
OF THE FIELD: Alzheimer's disease is the leading cause of dementia in the elderly, and there is no disease-modifying therapy yet available.
-
A single dose of solanezumab was generally well tolerated, although infusion reactions similar to those seen with administration of other proteins may occur with higher doses.
-
Mild-to-moderate AD patients were randomized to placebo or rosiglitazone (RSG) 2, 4 or 8 mg.
-
The problem with pure recombinant or synthetic antigens used in modern day vaccines is that they are generally far less immunogenic than older style live or killed whole organism vaccines.
-
To test whether antibodies against beta-amyloid are effective in slowing progression of Alzheimer's disease, we assessed cognitive functions in 30 patients who received a prime and a booster immunization of aggregated Abeta(42) over a 1 year period in a placebo-controlled, randomized trial.
-
Alzheimer's disease is the single biggest unmet medical need in neurology.
-
Immunization against amyloid-beta has been suggested as a possible preventive or therapeutic treatment for Alzheimer's disease.
-
Cerebrolysin is a peptidergic drug which displays neurotrophic action in various animal models.
From across this tag
9 of the 332 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer's disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial
- Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives
- Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval
- Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging
- Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health System
- Neuropathology of Anti-Amyloid-β Immunotherapy: A Case Report
- First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease
- [Anti-Amyloid Antibody Therapy for Alzheimer's Disease]
- The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis